作者:Alexander A. Spasov、Denis A. Babkov、Valentina A. Sysoeva、Roman A. Litvinov、Darya D. Shamshina、Evgeny N. Ulomsky、Konstantin V. Savateev、Viktor V. Fedotov、Pavel A. Slepukhin、Oleg N. Chupakhin、Valery N. Charushin、Vladimir L. Rusinov
DOI:10.1002/ardp.201700226
日期:2017.12
nitroazolopyrimidines were obtained by using nitration, chlorodeoxygenation, and amination reactions, and their antidiabetic properties were elucidated in vitro. It was shown that triazolo[1,5‐a]pyrimidine‐7(4H)‐ones exhibit a higher antiglycation activity than the corresponding 7‐alkylamino analogs and aminoguanidine, as the reference compound. It is suggested that this kind of activity can be associated with
预防晚期糖基化终末产物 (AGEs) 的形成是控制高血糖和糖尿病血管并发症相关发病机制的可靠方法。在这些方面,6-硝基唑并[1,5-a]嘧啶的新合成方法基于其结构类似物(如唑并[5,1-c][1,2, 4]三嗪-4(1H)-酮。通过硝化、氯代脱氧和胺化反应获得了许多硝基唑并嘧啶,并在体外阐明了它们的抗糖尿病特性。结果表明,三唑并[1,5-a]嘧啶-7(4H)-酮比相应的7-烷基氨基类似物和氨基胍(作为参考化合物)表现出更高的抗糖化活性。这表明这种活性可能与合成的 6-硝基-7-氧代衍生物所具有的螯合特性有关。此外,在体外测试了获得的化合物对二肽基肽酶 4 (DPP4)、糖原磷酸化酶和 α-葡萄糖苷酶的抑制活性,但证明它们的活性明显低于参考化合物。